The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Selecting between TKIs for patients with CML
In this video, Timothy Hughes, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, provides insight into selecting between available tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML). Prof. Hughes notes that clinicians should consider factors such as comorbidities and patient motivation for treatment-free remission. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’re very fortunate to have the first generation tyrosine kinase inhibitor imatinib, which is still a very good treatment and a very safe treatment. We have second generation, third generation, and now we’re seeing some allosteric inhibitors, including asciminib, but there are some others as well, that give us some advantages in terms of specificity at the target and probably giving us better tolerability overall...
We’re very fortunate to have the first generation tyrosine kinase inhibitor imatinib, which is still a very good treatment and a very safe treatment. We have second generation, third generation, and now we’re seeing some allosteric inhibitors, including asciminib, but there are some others as well, that give us some advantages in terms of specificity at the target and probably giving us better tolerability overall. So we have a number of choices. It’s a challenge for the clinician because all these drugs are good in their own way, but there’s no one drug that’s best for all patients. I think that a asciminib is a very effective drug in many cases, but there are some reasons why you may not use it for your patient. For instance, if they have significant cardiovascular risk profile in that setting, then imatinib still has its significant advantages. So I think you need to look at it in a patient-specific manner, considering the comorbidities and considering the motivation of the patient for treatment-free remission.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Related Videos
